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Background: We assessed the predictive accuracy of an empirically-derived score (weight
loss, insulin resistance, and glycemic control: “WIG”) to predict patients who will be suc-
cessful in reducing diabetes mellitus (DM) medication use with weight loss.
Methods: Case records of 121 overweight and obese patients with DM at two outpatient
weight management centers were analyzed.
Results: Mean period of follow-up was 12.5 ± 3.5 months. To derive the “WIG” scoring al-
gorithm, one point each was assigned to “W” (loss of 5% of initial body weight within the
first 3 months of attempting weight loss), “I” (triglyceride [TGL]/highdensity lipoprotein
ratio >3 [marker of insulin resistance] at baseline), and “G” (glycosylated hemoglobin [A1c
%] >8.5 at baseline). WIG score showed moderate accuracy in discriminating anti-DM dose
reductions at baseline, and after 3 months of weight loss efforts (likelihood ratios [LR] + >1,
LR <1, and area under the curve >0.7), and demonstrated good reproducibility.
Conclusions: WIG score shows promise as a tool to predict success with dose reductions of
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At a glance commentary
Scientific background of the subject
Intentional weight loss has the potential to result in
dose reductions of antidiabetes medications, which is a
strong motivating factor to a patient who is attempting
weight loss. However, not every patient who is success-
ful with weight loss is able to achieve dose reductions of
antidiabetes medications.
What this study adds to the field
The “WIG” score: “W” (loss of 5% of initial body
weight), “I” (triglyceride [TGL]/high-density lipoprotein
ratio 3 at baseline), and “G” (glycosylated hemoglobin
[A1c%] 8.5 at baseline) helps to identify patients, who
may be successful with dose reductions of antidiabetes
medications with intentional weight loss.
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[BMI]: 30 kg/m2) [1]. American adults who are overweight
(BMI: 25e29.9), obese (BMI: 30e39.9), and morbidly obese (BMI:
>40) have 1.59, 3.44, and 7.37 times higher odds, respectively,
of having diabetes mellitus (DM) [2]. Obesity and DM create
enormous healthcare costs, and the cost and adverse effects
of pharmacotherapy is a major contributor to the burden of
these conditions [3].
Intentional weight loss is associated with a decrease in the
need for antidiabetic (DM) medications [4e9]. However, not
everyone who loses weight is successful in reducing use of
these medications. Clinical trials assessing weight loss as an
intervention have used reduction in the need for medication
use as an important end point denoting success of the inter-
vention [7]. For a patient who is attempting weight loss, the
ability to dose reduce or stop using medications can be
objective evidence of success and a potential motivating fac-
tor. Weight loss trials have shown that motivation and
counseling are important factors associated with success and
adherence to attempts at weight loss [10,11]. We hypothesized
that developing a simple scoring system, using commonly
available clinical and biochemical parameters that can predict
an obese patient's probability of success with dose reductions
of antidiabetes medications when attempting weight loss,
would have clinical applicability in assisting practitioners in
patient counseling and individualizing the intensity of weight
loss intervention. Use of risk scores is common practice in the
care of patients with diabetes [12,13] and is known to improve
outcomes. Though clinically applicable scoring systems
assessing surgical weight loss efforts are available [13], a
clinically applicable score assessing nonsurgical weight loss
efforts is lacking.
This retrospective cohort study, involving overweight and
obese patients from two university-based weight manage-
ment programs, was used to develop a predictive score: The
weight loss, insulin resistance, glycemic control (“WIG”) score
and its components are weight loss of 5% achieved within the
first 3 months of attempting weight loss, triglyceride (TGL)/high-density lipoprotein (HDL) ratio 3 (a marker of insulin
resistance) [12e15] at the time of initiating weight loss, and
glycosylated hemoglobin (HbA1c%) 8.5 at the time of initi-
ating weight loss. We studied its utility for predicting success
with at least one dose reduction of any anti-DM medication.Materials and methods
Study setting and design
The study was conducted in two university-based specialty
outpatient weight management clinics, the Johns Hopkins
Weight Management Center in Baltimore, MD, and the George
Washington Weight Management program in Washington,
DC. A retrospective cohort design was chosen, and approval
was obtained from the Johns Hopkins Bloomberg School of
Public Health Institutional Review Board. Informed consent
waiver was granted by the Institutional Review Board.
Case records of patientswith a BMI>25 kg/m2 at the time of
enrollment into the twoweightmanagement programs during
the period March 2008 to January 2012 were assessed for
eligibility (total cohort). The study cohort consisted of patients
with a diagnosis of DM at the time of enrollmentwho reported
taking at least one antidiabetes medication. Patients were
excluded (excluded cohort) if they did not have a diagnosis of
DM at the time of enrollment into the weight management
programs.
Baseline data collection
Demographic data (age, gender, and race/ethnicity), cardio-
vascular risk factors (smoking, diabetes, and hypertension),
medication history (antidiabetes medications, anti-
hypertension medications, and lipid-lowering drugs), clinical
parameters (height, weight, systolic blood pressure, diastolic
blood pressure), and laboratory parameters (fasting glucose,
HbA1c, total cholesterol, low-density lipoprotein cholesterol
(LDL), HDL cholesterol, and TGL) were collected from the study
cohort at the time of entry into the weight management pro-
gram. BMI was calculated as per standard guidelines [16]. DM
was identified by physician diagnosis and medication usage.
Cohort description, patient follow-up, and weight
management intervention
Our cohort was an open cohort with regards to entry and exit.
Participants entered the cohort upon enrollment into our two
weightmanagement centers if they already had a diagnosis of
DM at the time of enrollment or upon physician reported a
diagnosis of incident DM during follow-up. Patients exited the
cohort if they achieved at least one dose reduction of any of
their anti-DM medications or were administratively censored
upon study conclusion in January of 2012.
The weight loss intervention protocols followed at the two
participating clinics were similar, and consisted of team-
based, comprehensive evaluation and treatment for weight
loss. The study participants had physician visits for follow-up
twice a month on average. The baseline visit consisted of a
physician-conducted medical history and physical
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dietary, behavioral, and exercise evaluations. Treatment was
individualized but typically consisted of an approximately
1000 kcal/day energy deficit diet, often utilizing meal re-
placements, a behavior modification plan, and a plan for
increasing physical activity utilizing both aerobic exercise and
strength training. These interventions with diet, physical ac-
tivity, and behavior modification were similar in both
participating institutions. Depending on treatment response,
the intervention was tailored to address individual patient
needs. The decision to alter the dose of or discontinue anti-
diabetic medications was based on the clinical judgment of
the treating physicians. During the follow-up period of the
study, if there was a documented reduction of 25% of daily
insulin dose (short acting and/or long acting insulin), it was
coded as one dose reduction for insulin. Factors considered in
deciding on dose reductions included themagnitude of weight
loss, glycemic control, hypoglycemic symptoms, and the pa-
tient's compliance with the weight management protocol.
Statistical analysis and “weight loss, insulin resistance,
glycemic control” score development
Continuous and categorical variables were expressed as
mean ± standard deviation and number (%), respectively. The
study cohort was categorized into those who achieved at least
one dose reduction of any anti-DMmedication and those who
did not; these two groups were compared using Student's t-
test or Chi-square test, as appropriate, with regard to baseline
demographic, clinical, and laboratory variables. From our
prior analyses using the same study population, we knew that
magnitude of weight loss, TGL/HDL ratio, and glycemic con-
trol (HbA1c) were associated with dose reductions of anti-
diabetes medications in our study cohort [5,6,15]. We
arbitrarily assigned numerical values to these three variables,
namely: 5% weight loss at 3 months after entry into our study
cohort (W) (coded as a categorical variable, yes/no), TGL/HDL
ratio 3 (a marker of insulin resistance; coded as a categorical
variable, yes/no) at the time of entry into the study cohort (I)
and HbA1c 8.5% (G) (coded yes/no) at the time of entry into
the study cohort, together forming the “WIG” score. The
rationale for using HbA1c cut-off of 8.5% was because this
showed the best predictive accuracy among other cut-offs
considered (9.5%, 9%, 8%, and 7.5%) in identifying pa-
tientswho achieved successful dose reductions of antidiabetic
medications with weight loss (Supplemental Table 1). Using
univariate logistic regression analysis, we assessed the asso-
ciation between these three variables, age (in years), gender
(male/female), smoking (yes/no), hypertension diagnosis (yes/
no), baseline BMI (continuous variable), and the dependent
variable: At least one dose reduction of any antidiabetes
medication (coded as yes/no). Variables thatwere significantly
associated (p < 0.05) with at least one dose reduction of any
antidiabetes medication in the univariate analysis were then
assessed for their association with at least one dose reduction
using multivariate logistic regression analysis to gauge their
strength of association (odds ratios). Goodness-of-fit of the
model was determined by means of Hosmer and Lemeshow's
goodness-of-fit test [17]. Based on the log-odds ratios (beta
coefficient) from the multivariate logistic regression analysis,a three-point scoring system named “WIG” score was devel-
oped, as these were the only variables that remained signifi-
cant in the multivariate logistic regression analysis. The
accuracy of the scoring system for predicting success with
achieving at least one dose reduction of any antidiabetes
medication was assessed using sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value, likeli-
hood ratio (LR)þ, LR, and area under receiver operator
characteristics (ROC) curve [17]. In the “WIG” score, variables
“I” and “G” are baseline variables as they can be assessed in a
patient at baseline. Variable “W” must be assessed at 3
months after an effort to lose weight has begun.
Simultaneous and sequential testing of the scoring system
We considered three clinical scenarios: (1) when a care pro-
vider is seeing a patient for the first time at the time of
enrollment into a weight management program, (2) when the
care provider is seeing the patient again after 3 months of the
patient's participation in a weight management program,
and (3) when the care provider is seeing the patient for the
first time, but the patient has already been actively involved
for the preceding 3 months in a weight management pro-
gram. For all three scenarios, we wanted to assess the pre-
dictive accuracy of the “WIG” score in predicting success with
antidiabetes medication dose reductions. For scenario 1, we
assessed if our participants were positive for baseline vari-
ables of the scoring system and accordingly assessed the
discrimination potential of these variables for antidiabetes
medication dose reductions. For scenario 2, we assessed the
predictive accuracy, by taking only those participants who
were positive for one or both baseline variables, and assessed
if they were also positive for the 3-month variable “W” of our
scoring system, i.e.,: “I” and “W” positive, “G” and “W” posi-
tive and “I” and “G” and “W” positive. This method, sequen-
tial testing, is used in diagnostic test research to improve the
specificity of the research tool [17]. For scenario 3, we
assessed simultaneously the baseline and emonth variables
of the scoring system on all study cohort participants, i.e.,
“W” or “I” or “G” positive. This method, simultaneous testing
of variables, is used in diagnostic test research, in this case to
improve sensitivity of the tool [17]. The ROC curves were
compared with one another using the method described by
DeLong et al. [18] A p  0.05 was considered statistically sig-
nificant. All analyses were performed using STATA 8.2, Illi-
nois, USA [19].
Testing reproducibility of “weight loss, insulin resistance,
glycemic control” score
Two of the authors, one an internist and another an MD, were
involved in this experiment. One of them was an internist,
with 5 years' postmedical school experience; the other was
also a physician with 3 years’ postmedical school experience.
Both authors received a brief 20 min training regarding
calculation of “WIG” score: Baseline variables, sequential
testing, and simultaneous testing. A computer generated
random sample (n ¼ 60) from the study cohort was selected.
First, the internist calculated “WIG” score for this random
study cohort patients, blinded with regard to patient and
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internist recalculated “WIG” score, for the same random
sample of study cohort participants after 2 days, blinded with
regard to earlier “WIG” score results, patient and medication
history. Agreementwas calculated comparing the present and
previous findings of the internist. Then, the physician calcu-
lated “WIG” score for the same random sample used by the
internist, blinded with regard to patient, and medication de-
tails. Agreement was calculated comparing the “WIG” score of
the internist with that of the physician. Kappa statistics was
used to assess intra- and inter-observer agreement in inter-
preting “WIG” score.Results
In total, 179 patient records (107 from Johns Hopkins and 72
from George Washington) were identified and reviewed. Of
these, 58 (32%) were excluded because they did not have a
diagnosis of DM at the time of enrollment into the programs.
The remaining 121 (68%) with a diagnosis of DM formed the
study cohort. By study exit, 81 (67%) in the study cohort
achieved at least one dose reduction of any antidiabetes
medication (dose reduction group). The remaining 40 (33%)
in the study cohort failed to achieve even one dose reduction
of their antidiabetes medications (nondose reduction group).
Baseline comparison between the dose reduction group and
the nondose reduction group is detailed in Table 1. Mean
period of follow-up in the dose reduction group was 13 ± 2.5
months and that in the nondose reduction group was
12.5 ± 2.5 months (p ¼ 0.511). Weight loss (16.9 ± 4.7 kg vs.
9.2 ± 3.1 kg, p ¼ 0.029) and HbA1c% reduction (0.7 ± 0.3 vs.
0.2 ± 0.1, p ¼ 0.035) in the dose reduction group was signif-
icantly greater than those in the nondose reduction group.
By the end of follow-up, TGL/HDL ratio in the dose-reductionTable 1 e Baseline characteristics of the study cohort.
Variables Study cohort (n ¼ 121) Dose reducti
Age (years) 51.8 ± 8.9 52.7
Males e n (%) 67 (55) 45 (
Caucasians e n (%) 90 (74) 63 (
African Americans e n (%) 31 (26) 18 (
Current smoking e n (%) 24 (20) 16 (
Duration of diabetes (years) 7.5 ± 2.5 8.0
Mean baseline weight (kg) 126.5 ± 18.2 127
Mean BMI (kg/m2) 36.1 ± 6.2 36.1
HbA1c% 8.2 ± 1.6 8.1
Mean TGL/HDL ratio 2.9 ± 1.2 3.1
HTN diagnosis - n (%) 102 (84) 69 (
MS e n (%) 68 (56) 45 (
Anti-HTN drugs e n (%) 102 (84) 69 (
Metformin- n (dose/day) 71 (1.7 g) 51 (
Sulfonylureas e n (%) 59 (49) 40 (
Glyburide e n (dose/day) 24 (10 mg) 16 (
Glipizide e n (dose/day) 21 (10 mg) 12 (
Glimepride e n (dose/day) 14 (2e4 mg) 9 (2
Sitagliptin e n (dose/day) 19 (100 mg) 11 (
Insulin e n (dose/day) 59 (60 ± 10 U) 45 (
Abbreviations: BMI: Body mass index; HbA1c: Glycosylated hemoglobin; T
lipoprotein; TGL: Triglycerides; HTN: Hypertension; MS: Metabolic syndrogroup and the nondose reduction group were 2.8 ± 0.6 and
2.5 ± 0.3, respectively. Though both groups achieved re-
ductions in TGL/HDL ratio by the end of follow-up (differ-
ence from baseline: 0.3 ± 0.5 in the dose reduction group
and 0.3 ± 0.4 in the nondose reduction group), this was not
significantly different when the two groups were compared
(p ¼ 0.114). The mean insulin dose at the end of follow-up
was 35 ± 10 and 55 ± 7 units in the dose reduction group
and the nondose reduction group, respectively (p ¼ 0.029).
The reduction from baseline dose of insulin to the insulin
dose at the end of follow-up was significantly better in the
dose reduction group (30 ± 10 units) compared to the
nondose reduction group (15 ± 12 units) (p ¼ 0.037). When
followed after the incident diabetes medication dose
reduction, 36% of participants reported weight gain during
the follow-up period of the study (4 ± 2 kg), 40% maintained
the weight loss and remained at the same body weight,
whereas the remaining 24% lost further body weight
(3 ± 1 kg). None of the study participants had to be dose-
increased until study completion, even those who regained
weight.
In the univariate logistic regression analysis, smoking,
hypertension diagnosis, baseline BMI, weight loss (W) of 5%
by 3 months after study entry, TGL/HDL ratio 3 (I) and
HbA1c 8.5% (G) were significantly associated with at least
one dose reduction of any antidiabetes medication [Table 2].
In multivariate logistic regression analysis, only weight loss
of 5% by 3 months after study entry (3-month variable), TGL/
HDL ratio 3 (baseline variable) and HbA1c 8.5% (baseline
variable) remained significantly associated with dose re-
ductions of antidiabetes medications, with log-odds ratios of
association of 2.41, 2.31, and 2.56, respectively [Table 2].
Hence, in the proposed “WIG” score, each of these variables
were assigned one point each, forming the three-point
scoring system.on group (n ¼ 81) Nondose reduction group (n ¼ 40) p
± 9.1 53.7 ± 9.3 0.133
56) 22 (55) 0.668
78) 27 (68) 0.042
22) 13 (32) 0.044
20) 8 (20) 0.996
± 2.0 7.5 ± 2.0 0.371
.1 ± 16.4 126.9 ± 19.3 0.417
± 5.5 35.6 ± 4.7 0.226
± 2.3 8.0 ± 1.7 0.179
± 0.8 2.8 ± 1.1 0.051
85) 33 (83) 0.067
56) 23 (58) 0.116
85) 33 (83) 0.067
1.7 g) 20 (1.7 g) 0.044
49) 19 (48) 0.133
10 mg) 8 (10 mg) 0.091
10 mg) 9 (10 mg) 0.046
e4 mg) 5 (2e4 mg) 0.117
100 mg) 8 (100 mg) 0.061
65 ± 7 U) 14 (60 U) 0.155
C: Total cholesterol; LDL: Low-density lipoprotein; HDL: High-density
me.
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Of the 121 study cohort participants, 94 (78%), 96 (79%), and
66 (54%) were positive for “I,” “G,” and “I and G,” respectively
[Table 3]. Area under the curve (AUC) was significantly
better in participants with both “I” and “G” compared to
those with only “I” positive (p ¼ 0.031) and only “G” positive
(p ¼ 0.031).
Scenario 2: sequential testing analysis
Of the 94 participants with “I” positive at baseline, 65 (69%)
were positive for both “I and W” [Table 3]. Of the 96 partici-
pants with “G” positive at baseline, 60 (63%) were positive for
both “G and W.” Of the 66 participants with both “I” and “G”
positive at baseline, 39 (59%) were positive for all three e “W,”
“I” and “G” variables. AUCs were similar in participants with
“I” and “W” positive, “G” and “W” positive, and all three pos-
itive (all p > 0.05).
Scenario 3: simultaneous testing analysis
Of the 121 study cohort participants, 97 (80%) had either “W”
or “I” or “G” positive [Table 3]. Sensitivitywas 95%,with AUC of
0.70, which was significantly lower than the AUC with base-
line variables (both I and G, AUC ¼ 0.79) (p ¼ 0.041), and
sequential testing (all three variables positive, AUC ¼ 0.77)
(p ¼ 0.048). Fig. 1 details the difference in ROC curves between
simultaneous and sequential testing.
Reproducibility of “weight loss, insulin resistance, glycemic
control” score
The intra- and inter-observer agreements in the calculation of
“WIG” score for baseline variables, sequential testing, and
simultaneous testing were 0.99e1.00.Discussion
Our retrospective cohort study involving overweight and
obese participants from two tertiary care weightmanagement
programs has shown “WIG” score to have moderately good
accuracy and reliability for discriminating patients who willTable 2 e Associations with antidiabetes medication dose red
Variables zUnivariate analysis
Log-OR (95% CI) p
Age 1.05 (0.81e2.98) 0.211
Gender 1.45 (0.64e3.01) 0.179
Hypertension 1.21 (1.01e2.03) 0.033
Smoking 1.18 (1.01e1.99) 0.039
Baseline BMI 1.13 (1.04e2.66) 0.030
Weight loss (5%) (W) 2.47 (2.25e3.00) 0.021
TGL/HDL ratio 3 (I) 2.46 (2.10e3.86) 0.018
HbA1c 8.5% (G) 2.49 (2.18e3.17) 0.028
Abbreviations: zLogistic regression analysis; BMI: Body mass index; OR: O
protein; TGL: Triglycerides.be successful in achieving at least one dose reduction of anti-
DM medication when attempting weight loss. The compo-
nents of the “WIG” score worked well in all three clinical
scenarios [Table 3] (scenario 1: I and G components, scenario
2: I and G for baseline and WIG for sequential testing at 3
months and scenario 3: All three components such as W, I,
and G for simultaneous testing). Mechanistically, “WIG” score
with its component variables “I,” “G” and “W” ties together
weight loss and its associated reduction in insulin resistance
with success at achieving anti-DM medication dose re-
ductions. Weight loss lowers insulin resistance by changing
fat mass and modifying the release of adipocytokines such as
leptin, adiponectin, and resistin [20,21]. Reduction in insulin
resistance results in better glycemic control and thus de-
creases the need for anti-DM medications [7]. Prior work on
scores for assessing the effect of medical management of
obesity on DM are very limited. The DiaRem score, used for
pre-operative prediction of diabetes remission following bar-
iatric surgery, relies on insulin use, age, HbA1c%, and type of
anti-DM medication used to predict remission of diabetes
postoperatively [11]. Mechanistically, the component vari-
ables of DiaRem score strongly weighs on anti-DMmedication
use, which reflect a patient's baseline preoperative insulin
resistance and glycemic control to predict postoperative dia-
betes remission, similar to the concept underlying the “WIG”
score.
In the assessment of the predictive accuracy of the “WIG”
score in the three clinical scenarios, there was a wide range of
sensitivities and specificities [Table 3]. Baseline variables,
though sensitive, lacked specificity [Table 3]. Sequential
testing improved specificity, as expected [Table 3]. Although
simultaneous testing improved sensitivity (95%), it lacked
specificity (50%). Sequential testing showed good PPV (>90%)
[Table 3]. With sequential and simultaneous testing, “WIG”
score showed LRþ, LR, and AUC values >1, <1 and >0.7,
respectively, which should be interpreted as denoting mod-
erate predictive accuracy [15], though baseline variables “I”
alone or “G” alone showed poor AUC (0.60) whereas “I” and “G”
at baseline had a AUC of 0.79 [Table 3].
The high incidence of dose reductions observed in our
study cohort may have been due to surveillance bias, the in-
tensity of weight loss interventions offered, and the decision
to dose reduce being subjective and at the discretion of the
treating physicians. However, this may not affect the validityuctions and relative weights of each variable.
zMultivariate analysis Relative weights
Log-OR (95% CI) p
1.01 (0.77e2.32) 0.216 e
1.15 (0.67e2.37) 0.210 e
0.96 (0.42e1.92) 0.132 e
1.07 (0.66e2.11) 0.286 e
1.07 (0.81e2.35) 0.131 e
2.41 (2.19e2.76) 0.031 1
2.31 (2.03e3.41) 0.022 1
2.56 (2.12e2.93) 0.030 1
dds ratio; HbA1c: Glycosylated hemoglobin; HDL: High-density lipo-
Table 3 e Predictive accuracy of “WIG” score in discriminating patients who could achieve at least 1 dose reduction.
Predictive accuracy Study cohort (n ¼ 121)
Scenario 1 (baseline variables) Scenario 2 (sequential testing) Scenario 3 (simultaneous testing)
“I” only “G” only “IG” both “IW” “GW” “GIW” “W or I or G”
Sensitivity (%) 87 88 74 80 80 75 95
Specificity (%) 43 38 85 78 80 79 50
PPV 76 74 91 94 94 90 79
NPV 63 60 62 49 52 56 83
LRþ 1.52 1.40 4.94 3.61 4.01 3.5 1.9
LR 0.29 0.33 0.31 0.25 0.25 0.32 0.10
AUC 0.61 0.60 0.79 0.78 0.79 0.77 0.70
Number of participants 121 121 121 94 96 66 121
Number achieving 1
dose reduction
81 81 81 76 60 47 81
Number with this score 94 96 66 65 60 39 97
Number achieving 1 dose
reduction with this score
71 71 60 61 54 35 77
Abbreviations: PPV: Positive predictive value; NPV: Negative predictive value; LR: Likelihood ratio; AUC: Area under the curve.
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and effect relationship in our study, in which case surveil-
lance bias may be a significant internal validity issue. Rather,
we are developing a risk score for use in the population of
overweight and obese patients who attempted weight loss
through a structured effort.
The utility of the “WIG” score may potentially extend to
discriminating patients who may fail medical management
and may be better candidates for bariatric surgery. This is
because “WIG” score works well in those patients who have at
baseline low insulin resistance (TGL/HDL ratio <3) and better
glycemic control (HbA1c% <8.5) and thus will potentially
benefit from medical management whereas those with poor
baseline glycemic control (HbA1c% >8.5) and high baseline
insulin resistance (TGL/HDL >3) may fail by “WIG” score and
be better candidates for bariatric surgery. The “WIG” scoreFig. 1 e Comparison between the ROC curves of “WIG” score
using simultaneous and sequential testing strategy in
discriminating patients who can achieve dose reductions of
antidiabetic medications following weight loss. ROC:
Receiver operating characteristics curve; WIG: Weight loss,
insulin resistance, glycemic control.could also be of value in the setting of bariatric surgery, like
the “DiaRem” score [13], as bariatric surgery is a better tool to
improve insulin resistance thanmedicalmanagementwith its
potential to work with incretin gut hormones in addition to
the adipocytes [22,23].Limitations
Because of the small sample size of our study population, we
could not internally validate our score, nor perform subgroup
analyses by BMI class and racial differences nor study the
score's validity in predicting reductions in the dose of specific,
individual antidiabetes medications. Validation and poten-
tially subgroup analyses could be accomplished using data
from large medical weight loss trials [4,7]. In addition, the
“WIG” score may not be generalizable to primary care-based
weight loss efforts. This can be studied using data from
weight loss trials which were primary care based [10,11]. We
observed significantly greater magnitudes of weight loss
(15.4 kg by 15months of follow-up) compared to typical weight
loss trials (weight loss: 4e6 kg within 12e15 months of follow-
up) [10,11]. It is thus possible that confounding due to un-
known factors may have played a role. Finally, the retro-
spective cohort design limited us to what was consistently
recorded in patient charts; for example, we did not have data
on waist circumference, whichmight also have relevance as a
predictor. In the same note, the reasons for dose reductions of
antidiabetic medications were not consistently documented
in the case records. However, since these dose-reductions
accompanied a significant reduction in HbA1c% by the end
of follow-up, we may infer that dose reductions possibly
happened due to the beneficial glucose-lowering effects of
weight loss.Conclusions
“WIG” score shows promise as a tool to predict success with
dose reduction of at least one antidiabetes medication in
overweight and obese DM patients who attend structured
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 8 8e1 9 4194weight management programs. In addition, “WIG” score may
potentially have wider applicability in assessing interventions
such as bariatric surgery, where insulin resistance reduction
is the central mechanism of action. Before advocating wide-
spread clinical use, this tool should be prospectively validated
in large weight loss trials [4,7,10,11]. Use of “WIG” score in a
primary care setting should also be studied.Financial support and sponsorship
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